EW — Edwards Lifesciences Corporation

Edwards Lifesciences (EW) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Sales Growth: Q3 sales increased by 12.6% year-over-year to $1.55 billion, driven by strong performance across multiple therapeutic areas.
• TAVR Sales: Global TAVR sales reached $1.15 billion, up 10.6% from the prior year.
• Earnings Per Share (EPS): Adjusted EPS was $0.67, exceeding expectations, while GAAP EPS was $0.50.
• Gross Profit Margin: Adjusted gross profit margin was 77.9%, down from 80.7% year-over-year, primarily due to foreign exchange and operational expenses.
• R&D and SG&A Expenses: R&D expenses were $281 million (18.1% of sales), while SG&A expenses were $515 million (33.1% of sales).

2. Strategic Updates and Business Highlights

• Product Portfolio: Continued focus on structural heart therapies, including TAVR, mitral, and tricuspid valve treatments, with significant clinical data presented at the TCT conference.
• TAVR Innovations: The SAPIEN platform demonstrated strong long-term outcomes, with new guidelines promoting earlier intervention for severe aortic stenosis.
• TMTT Growth: The TMTT product group saw a 53% increase in sales to $144 million, driven by PASCAL and EVOQUE systems.
• Surgical Segment: Surgical sales grew 5.6% to $258 million, supported by the RESILIA portfolio.

3. Forward Guidance and Outlook

• Sales Growth Guidance: Full-year sales growth guidance raised to the high end of 9% to 10%. TAVR sales growth guidance increased to 7% to 8%.
• EPS Guidance: Adjusted EPS guidance for the full year is now between $2.56 and $2.62.
• Long-term Growth: Confidence in sustainable growth driven by multiple product lines and ongoing clinical evidence supporting TAVR and TMTT therapies.

4. Bad News, Challenges, or Points of Concern

• Margin Pressure: Adjusted gross profit margin decreased year-over-year, with expectations of continued pressure from foreign exchange rates.
• CFO Transition: Scott Ullem announced his planned transition out of the CFO role by mid-2026, raising concerns about leadership continuity.
• Regulatory Risks: Uncertainty surrounding the JenaValve regulatory approval and the potential impact of FTC actions.

5. Notable Q&A Insights

• TAVR Performance: Management emphasized that Q3's strong TAVR growth was not solely due to asymptomatic approval but rather a combination of renewed clinical focus and favorable seasonal trends.
• Future Growth Drivers: The company sees significant potential in treating previously undiagnosed patients and anticipates that new guidelines will further enhance TAVR adoption.
• Tricuspid and Mitral Valve Adoption: The positive reception of EVOQUE data is expected to accelerate adoption in tricuspid treatments, with similar expectations for the upcoming SAPIEN M3 launch in mitral valve therapies.
• Operational Efficiencies: Ongoing initiatives to improve cath lab efficiency and patient outcomes are in place, leveraging AI and educational programs to enhance capacity and streamline procedures.

Overall, Edwards Lifesciences reported a strong Q3 performance, with positive growth across its product lines and a confident outlook for the future, despite some challenges related to margins and regulatory uncertainties.